Castle Biosciences, Inc. Stock News

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced oral presentations on its DecisionDx® skin cancer tests at the American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting.

Level Four Advisory Services LLC purchased a new stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) in the 3rd quarter, Holdings Channel.com reports. The fund purchased 5,265 shares of the companys stock, valued at approximately $350,000. Several other hedge funds have also added to or reduced their stakes in CSTL. Dimensional Fund Advisors LP raised []

Castle Biosciences, Inc. (NASDAQ:CSTL) saw a large decrease in short interest in October. As of October 29th, there was short interest totalling 846,200 shares, a decrease of 14.8% from the October 14th total of 992,900 shares. Based on an average daily volume of 168,500 shares, the short-interest ratio is currently 5.0 days. Approximately 4.8% of []

Equities analysts expect that Castle Biosciences, Inc. (NASDAQ:CSTL) will post sales of $23.43 million for the current quarter, according to Zacks. Two analysts have issued estimates for Castle Biosciences earnings. The highest sales estimate is $23.45 million and the lowest is $23.40 million. Castle Biosciences posted sales of $17.30 million in the same quarter last []

Wall Street brokerages expect Castle Biosciences, Inc. (NASDAQ:CSTL) to post earnings per share (EPS) of ($0.43) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Castle Biosciences earnings. The lowest EPS estimate is ($0.47) and the highest is ($0.39). Castle Biosciences reported earnings per share of ($0.16) in []

The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to its

Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2021 Results - Earnings Call Transcript

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle will release its financial results for the third quarter and nine months ended Sept. 30, 2021, after the close of market on No

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced that it has been awarded a five-year U.S. Federal Supply Schedule (FSS) contract for its DecisionDx®-Melanoma test.

Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q2 2021 Results - Earnings Call Transcript

After the market close on Monday, Castle Biosciences Inc (NASDAQ: CSTL) reported that its second-quarter revenues rose 79% Y/Y to $22.75 million, beating the consensus of $18.93 million. The increa

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -17.24% and 19.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stoc

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences announced oral data presentations on two of its skin cancer gene expression profile tests during the 2021 AAD Summ

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle today announced its continued collaboration with the Melanoma Research Foundation (MRF).